The REVERSE trial cohort evaluating cardiac resynchronization therapy included 610 patients with a mean age of 62.5 years who were on better pharmacologic treatment than previous trial cohorts.
RCT (n=610)
Yes
Does cardiac resynchronization therapy improve outcomes in patients with asymptomatic left ventricular dysfunction with previous symptoms of mild heart failure?
The REVERSE study enrolled a younger, better medically treated cohort with narrower QRS width compared to previous CRT trials, focusing on mild or asymptomatic heart failure.
The Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study is a randomized controlled trial currently assessing the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular (LV) dysfunction with previous symptoms of mild heart failure. This paper describes the baseline characteristics of randomized patients; 610 patients with New York Heart Association (NYHA) class II (82.3%) heart failure or asymptomatic (NYHA class I) LV dysfunction with previous symptoms (17.7%) were randomized in 73 centers. The mean age was 62.5+/-11.0 years, the mean LV ejection fraction was 26.7%+/-7.0%, and the mean LV end-diastolic diameter was 66.9+/-8.9 mm. A total of 97% of patients were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 95.1% were taking beta-blockers, which were at the target dose in 35.1% of patients. Compared with previous randomized cardiac resynchronization therapy trials, REVERSE patients are on better pharmacologic treatment, are younger, and have a narrower QRS width despite similar LV dysfunction.
Linde et al. (Sat,) conducted a rct in Asymptomatic left ventricular dysfunction with previous symptoms of mild heart failure or NYHA class II heart failure (n=610). Cardiac resynchronization therapy was evaluated. The REVERSE trial cohort evaluating cardiac resynchronization therapy included 610 patients with a mean age of 62.5 years who were on better pharmacologic treatment than previous trial cohorts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: